Diffuses grosszelliges B-Zell-Lymphom (DLBCL)

Abkürzungen: 

CAR-T: Chimäre Antigenrezeptor T-Zellen, CD: Cluster of Differentiation, CR: Komplettes Ansprechen (complete response), CRS: Zytokinfreisetzungssyndrom (cytokine release syndrome), DOR: Ansprechdauer (duration of response), DLBCL: Diffuses grosszelliges B-Zell-Lymphom (Diffuse large B-Cell Lymphoma), ECOG PS: Eastern Cooperative Oncology Group Performance Status, Fc-Region: Fragmentierte Kristallisationsregion, ICANS: Immuneffektorzell-assoziiertes Neurotoxizitätssyndrom (immune effector cell-associated neurotoxicity syndrome), KI: Konfidenzintervall (confidence interval), ORR: Gesamtansprechrate, OS: Gesamtüberleben (overall survival), PFS: Progressionsfreies Überleben (progression free survival), r/r: rezidivierend oder refraktär, SLC: Syndrome de libération de cytokines,TTR: Zeit bis zum Ansprechen (time to response)

Referenzen: 

1. Jurczak W., et al. Longer Follow-up From the Pivotal EPCORE NHL-1 Trial Reaffirms Subcutaneous Epcoritamab Induces Deep, Durable Complete Remissions in Patients with Relapsed/Refractory Large B-cell Lymphoma. Poster and Abstract presented at EHA 2023. P1118.

2. Fachinformation TEPKINLY^® (Epcoritamab). www.swissmedicinfo.ch

3. Thieblemont C., et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41(12): 2238–2247.

4. Engelberts P. J., et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52: 102625.

5. Hutchings M., et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021 Sep 25;398(10306): 1157–1169.

Die Referenzen können durch Fachpersonen bei medinfo.ch@abbvie.com angefordert werden.